Anti-cd20 glycoantibodies and uses thereof
AssigneeAcademia Sinica
InventorsChi-Huey WONG, Chung-Yi WU, Ming-Hung Tsai
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
Claims21
A method for increasing antibody-dependent cellular cytotoxicity (ADCC) activity comprising administering to a patient in need thereof an effective amount of a composition of anti-CD20 glycoantibodies or anti-CD20 binding fragments comprising an isolated homogeneous population of anti-CD20 IgG molecules, wherein the anti-CD20 IgG molecules have been glycoengineered and have the same N-glycan on each of the Fc region;
- wherein:
- the N-glycan is free of fucose;
- the N-glycan is selected from the group consisting of
- Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-6)Gal2GlcNAc3Man3GlcNAc2,
- Sia2(α2-3)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-3)Gal2GlcNAc3Man3GlcNAc2,
- Sia2(α2-3/α2-6)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-6/α2-3)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-3/α2-6)Gal2GlcNAc3Man3GlcNAc2,
- Sia2(α2-6/α2-3)Gal2GlcNAc3Man3GlcNAc2,
- Sia(α2-6)Gal2GlcNAc2Man3GlcNAc2,
- Sia(α2-3)Gal2GlcNAc2Man3GlcNAc2,
- Sia(α2-6)Gal2GlcNAc3Man3GlcNAc2,
- Sia(α2-3)Gal2GlcNAc3Man3GlcNAc2,
- Sia(α2-6)GalGlcNAc2Man3GlcNAc2,
- Sia(α2-3)GalGlcNAc2Man3GlcNAc2,
- Sia(α2-6)GalGlcNAc3Man3GlcNAc2, and
- Sia(α2-3)GalGlcNAc3Man3GlcNAc2;
- and
- wherein the glycoengineered anti-CD20 IgG molecules have increased ADCC activity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
A method for the treatment of cancer in a patient and/or improving disease treatment based on B-cell depletion comprising administering to the patient in need thereof an effective amount of a composition of anti-CD20 glycoantibodies or anti-CD20 binding fragments comprising an isolated homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of the Fc region;
- wherein:
- the N-glycan is free of fucose;
- the anti-CD20 IgG molecules have increased ADCC activity compared to the corresponding monoclonal antibodies that have not been glycoengineered;
- and
- the N-glycan is selected from the group consisting of
- Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-6)Gal2GlcNAc3Man3GlcNAc2,
- Sia2(α2-3)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-3)Gal2GlcNAc3Man3GlcNAc2,
- Sia2(α2-3/α2-6)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-6/α2-3)Gal2GlcNAc2Man3GlcNAc2,
- Sia2(α2-3/α2-6)Gal2GlcNAc3Man3GlcNAc2,
- Sia2(α2-6/α2-3)Gal2GlcNAc3Man3GlcNAc2,
- Sia(α2-6)Gal2GlcNAc2Man3GlcNAc2,
- Sia(α2-3)Gal2GlcNAc2Man3GlcNAc2,
- Sia(α2-6)Gal2GlcNAc3Man3GlcNAc2,
- Sia(α2-3)Gal2GlcNAc3Man3GlcNAc2,
- Sia(α2-6)GalGlcNAc2Man3GlcNAc2,
- Sia(α2-3)GalGlcNAc2Man3GlcNAc2,
- Sia(α2-6)GalGlcNAc3Man3GlcNAc2, and
- Sia(α2-3)GalGlcNAc3Man3GlcNAc2.
Dependencies are inferred from the claim text.